
For research use only. We do not supply to patients.
For pharmaceutical-grade products or other inquiries, please contact our experts.
Kolli S, et al. conducted a randomized comparative effectiveness trial enrolled 162 emergency department patients aged ≥65 years with acute severe pain (median baseline pain score 10/10) to receive either 1,000 mg intravenous acetaminophen or 0.5 mg intravenous hydromorphone. At 60 minutes, pain improvement was 3.6 points with acetaminophen and 4.6 points with hydromorphone (difference 1.0; 95% CI 0.1–2.0). Although statistically superior, this difference did not meet the predefined minimum clinically important difference of 1.3 points.
Fig. 1 Graphical depiction of participant-level pain scores at baseline and 60 minutes (Kolli S, et al., 2022)
References
Shi J, et al. investigated the protective effects of hydromorphone pretreatment against lung injury caused by CO₂ pneumoperitoneum in mouse models and in patients undergoing laparoscopic gynecological surgery. In mice, hydromorphone alleviated lung injury, reduced oxidative stress markers (myeloperoxidase, total oxidant status), increased antioxidant capacity, upregulated heme oxygenase-1 (HO-1) expression, and improved mitochondrial morphology and dynamics. These protective effects were abrogated by HO-1 siRNA, confirming the essential role of HO-1. In clinical patients, hydromorphone pretreatment resulted in lower serum levels of lung injury markers (CC-16, ICAM-1), a reduced prooxidant-antioxidant balance, and higher HO-1 activity compared to morphine.
Fig. 2 Hydromorphone alleviates pneumoperitoneum-induced lung injury in mice. (Shi J, et al, 2021)
References
Cat NO.: API5907380-2
CAS NO.: 5907-38-0
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
All our products are chemicals for research purposes only. We do not supply for human or veterinary applications.
Privacy Policy | Cookie Policy Copyright © Protheragen. All Rights Reserved.
